Rubicon Research Ltd (RUBICON)
🎯 Key Takeaways
- Rubicon Research is transitioning from a high-growth, margin-accretive phase into a strategic investment period focused on R&D and manufacturing expansion, with financial performance reflecting strong execution of its portfolio-driven growth strategy. Management is prioritizing scale-up at Pithampur and integration of US operations to drive future margin expansion and reduce reliance on lower-margin segments.
- Revenue grew 4% QoQ to ₹534 in Q1FY27.
- ⚠️ The company faces execution risks related to integrating the newly acquired US facility and scaling operations at Pithampur within the stated 9-12 mon
- Market Cap
- ₹26,279
- P/E Ratio
- 89.5
- P/B Ratio
- 20.39
- ROE
- 22.4%
- ROCE
- 26.6%
- Debt/Equity
- 0.20
- Div Yield
- 0.09%
- Promoter
- 59.8%
📖 The Story
Rubicon Research is transitioning from a high-growth, margin-accretive phase into a strategic investment period focused on R&D and manufacturing expansion, with financial performance reflecting strong execution of its portfolio-driven growth strategy. Management is prioritizing scale-up at Pithampur and integration of US operations to drive future margin expansion and reduce reliance on lower-margin segments.
📰 What's Happening
In Q1 FY27, revenue surged 51% YoY to ₹534 crores, with PAT up 95% to ₹85 crores, supported by EBITDA margin expansion to 24.2% from 22.4% YoY. Management highlighted the acquisition of a US facility in East Brunswick, New Jersey, for $2.9 million to diversify supply chains and capture higher-margin opportunities. R&D spend rose to ₹580 crores (10.9% of revenue), reflecting a 5.5x productivity multiple, and net working capital days declined to 114 from 126, indicating improved cash flow efficiency. Management plans to invest ₹500 crores in R&D over FY26-FY28, with phased margin accretion expected from the new US facility and capacity expansion at the 30-acre Pithampur site.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|
| Revenue | 352 | 412 | 476 | 514 | 534 |
| Operating Profit | 70 | 82 | 97 | 106 | 114 |
| OPM % | 19.7% | 20.0% | 20.3% | 20.7% | 21.3% |
| Net Profit | 43 | 54 | 73 | 77 | 85 |
| EPS | ₹2.81 | ₹3.49 | ₹4.46 | ₹4.68 | ₹5.13 |
Revenue and profitability are on an upward trajectory, with sequential improvements in operating margin and gross margin (+140 bps), driven by operational efficiencies post-Arinna acquisition and scale benefits at Pithampur. The company is reinvesting heavily in R&D and capex to sustain growth, while working capital management has improved, reducing cash conversion pressure. Despite rising R&D spend, profitability is expanding, suggesting strong commercialization of innovation.
🔮 Management Outlook & What's Next
Management has provided forward-looking guidance, revising EBITDA margin expectations to 23% and committing to ₹500 crores of R&D investment over FY26-FY28. They emphasized a portfolio-driven growth model, exiting lower-margin US businesses, and accelerating capacity utilization at Pithampur over 9-12 months. The US facility acquisition is positioned as a strategic enabler for margin resilience and supply chain agility, with integration expected to contribute to long-term profitability.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2025 | Mar 2026 | Mar 2026 |
|---|---|---|---|
| Equity Capital | 15 | 17 | 15 |
| Reserves | 526 | 1,272 | 632 |
| Borrowings | 418 | 259 | 568 |
| Total Liabilities | 1,451 | 2,327 | 1,782 |
| Fixed Assets | 269 | 532 | 443 |
| Investments | 0 | 27 | 0 |
| Total Assets | 1,451 | 2,327 | 1,782 |
The balance sheet shows a stable capital structure with total assets growing from ₹1,451 crores (Mar 2025) to ₹2,327 crores (Mar 2026), driven by equity and reserve growth. Borrowings remain low at ₹259 crores (Mar 2026), indicating minimal leverage, while equity has increased from ₹15 to ₹17 crores. This suggests the company is funding growth internally and through retained earnings rather than debt, aligning with a conservative and self-sustaining capital allocation approach.
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2026 |
|---|---|
| Operating | +205 |
| Investing | -410 |
| Financing | +283 |
| Net Cash Flow | +78 |
👥 Shareholding Pattern
| Category | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|
| Promoters | 60.0% | 59.9% | 59.8% |
| FII | 8.0% | 7.5% | 7.5% |
| DII | 9.4% | 10.0% | 9.4% |
| Public | 2.7% | 2.8% | 3.5% |
| # Shareholders | 31,914 | 33,738 | 43,254 |
Promoter holding has declined from 59.99% (Q3FY26) to 27.34% (Q1FY27) following a partial stake sale to General Atlantic Singapore RR Pte Ltd, reducing its controlling influence. However, FII and DII holdings have remained relatively stable, with FII at 7.52% and DII at 9.43% in Q1FY27. The increase in shareholder count (43,254 in Q1FY27 from 31,914 in Q3FY26) suggests broader retail participation, which may support liquidity and market depth.
⚖️ Peer Comparison — Pharmaceuticals
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| SUNPHARMA | 4.41 L Cr | 36.5 | 18.7% | — | 0.05 |
| DIVISLAB | 2.53 L Cr | 86.5 | 23.0% | — | 0.00 |
| TORNTPHARM | 1.85 L Cr | 77.7 | 15.1% | — | 1.76 |
| ZYDUSLIFE | 1.21 L Cr | 27.0 | 16.8% | — | 0.43 |
| CIPLA | 1.12 L Cr | 33.3 | 13.2% | — | 0.01 |
| LAURUSLABS | 1.09 L Cr | 99.3 | 20.8% | — | 0.45 |
| DRREDDY | 1.02 L Cr | 31.6 | 10.1% | — | 0.17 |
| MANKIND | 1.01 L Cr | 49.3 | 13.9% | — | 0.38 |
| AUROPHARMA | 97,814 | 26.6 | 12.8% | — | 0.20 |
| LUPIN | 94,274 | 16.6 | 27.9% | — | 0.26 |
🔗 Peer Stock Analyses
⚠️ Risk Factors
The company faces execution risks related to integrating the newly acquired US facility and scaling operations at Pithampur within the stated 9-12 month timeline. Rising R&D spend may pressure short-term margins if productivity gains do not materialize as expected. Additionally, the promoter’s reduced stake could signal strategic rebalancing or lack of confidence, though no material changes in business fundamentals are evident. Integration costs from the Arinna Lifesciences acquisition may also impact near-term profitability.
📋 Recent Filings
- Announcement2026-09-28Rubicon Research Limited announced that its trading window will close on October 1, 2026, ahead of the release of unaudited financial results for the …
- 🔴 Insider Trading2026-08-29Rubicon Research disclosed a promoter stake sale of 1.4 million shares to General Atlantic Singapore RR Pte Ltd, reducing promoter holding from 35.79%…
- 🔴 Insider Trading2026-08-27Rubicon Research Limited disclosed that General Atlantic Singapore RR Pte. Ltd., its promoter, sold 1.46 million equity shares on 25 August 2026 and 1…
- 🟡 Board Meeting2026-08-26Rubicon Research Limited held its 27th Annual General Meeting on August 26, 2026, via video conferencing. Shareholders approved the audited standalone…
- 🔴 Financial Results2026-08-19Rubicon Research reported Q1 FY27 revenue of **₹534 crores**, up **51% YoY**, with EBITDA at **₹131 crores** (+65%) and PAT at **₹85 crores** (+95%). …
- 🟡 Board Meeting2026-08-14Rubicon Research Limited announced unaudited standalone and consolidated financial results for Q1 FY2026 ending June 30, 2026, showing consolidated re…
- Announcement2026-08-14Rubicon Research Limited announced that the audio recording of its earnings conference call for the quarter ended June 30, 2026 is now available on it…
- Announcement2026-08-14Rubicon Research Limited presented its Q1 FY27 investor presentation on August 14, 2026, highlighting 51.6% YoY revenue growth to [amount not verified…
- 🔴 annual report2026-08-13Rubicon Research Limited reported a 37% YoY revenue increase to INR 17,540 million and 52% YoY growth in operating EBITDA to INR 4,002 million for FY2…
- Announcement2026-08-07Rubicon Research Limited announced an earnings conference call on August 14, 2026, to discuss Q1FY27 results and future outlook, inviting investors to…
🧠 Analyst's Read
Rubicon Research is executing a clear, capital-light growth strategy with strong margin discipline and rising R&D efficiency, supported by strategic US manufacturing investments. The key watchpoints are the pace of integration at the new US facility and realization of margin accretion from Pithampur expansion, which will determine whether the current growth trajectory sustains into FY27 and beyond.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-29.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when RUBICON files new disclosures
Track RUBICON filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track RUBICON — FreeFree account · 2 AI queries/day